» Articles » PMID: 32202936

Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary

Abstract

Heart failure with preserved ejection fraction (HFpEF), a major public health problem that is rising in prevalence, is associated with high morbidity and mortality and is considered to be the greatest unmet need in cardiovascular medicine today because of a general lack of effective treatments. To address this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working group made up of experts in HFpEF and novel research methodologies to discuss research gaps and to prioritize research directions over the next decade. Here, we summarize the discussion of the working group, followed by key recommendations for future research priorities. There was uniform recognition that HFpEF is a highly integrated, multiorgan, systemic disorder requiring a multipronged investigative approach in both humans and animal models to improve understanding of mechanisms and treatment of HFpEF. It was recognized that advances in the understanding of basic mechanisms and the roles of inflammation, macrovascular and microvascular dysfunction, fibrosis, and tissue remodeling are needed and ideally would be obtained from (1) improved animal models, including large animal models, which incorporate the effects of aging and associated comorbid conditions; (2) repositories of deeply phenotyped physiological data and human tissue, made accessible to researchers to enhance collaboration and research advances; and (3) novel research methods that take advantage of computational advances and multiscale modeling for the analysis of complex, high-density data across multiple domains. The working group emphasized the need for interactions among basic, translational, clinical, and epidemiological scientists and across organ systems and cell types, leveraging different areas or research focus, and between research centers. A network of collaborative centers to accelerate basic, translational, and clinical research of pathobiological mechanisms and treatment strategies in HFpEF was discussed as an example of a strategy to advance research progress. This resource would facilitate comprehensive, deep phenotyping of a multicenter HFpEF patient cohort with standardized protocols and a robust biorepository. The research priorities outlined in this document are meant to stimulate scientific advances in HFpEF by providing a road map for future collaborative investigations among a diverse group of scientists across multiple domains.

Citing Articles

Mechanisms of exercise intolerance in hear-t failure with preserved ejection fraction (HFpEF).

Pecchia B, Samuel R, Shah V, Newman E, Gibson G Heart Fail Rev. 2025; .

PMID: 40080287 DOI: 10.1007/s10741-025-10504-3.


Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes.

Henry A, Mo X, Finan C, Chaffin M, Speed D, Issa H Nat Genet. 2025; .

PMID: 40038546 DOI: 10.1038/s41588-024-02064-3.


Melatonin as a Novel Drug to Improve Cardiac Function and Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis.

Daliri A, Goudarzi N, Harati A, Kabir K Clin Cardiol. 2025; 48(3):e70107.

PMID: 40026259 PMC: 11873767. DOI: 10.1002/clc.70107.


Dysregulated fatty acid metabolism in pericardiac adipose tissue of pulmonary hypertension due to left heart disease mice.

Qiu H, Chen J, Mei Z, Chen W, Jun L, Chen Y FASEB J. 2025; 39(3):e70355.

PMID: 39932146 PMC: 11812284. DOI: 10.1096/fj.202402842R.


Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction.

Rasooly D, Giambartolomei C, Peloso G, Dashti H, Ferolito B, Golden D Nat Cardiovasc Res. 2025; .

PMID: 39915329 DOI: 10.1038/s44161-025-00609-1.


References
1.
Loffredo F, Nikolova A, Pancoast J, Lee R . Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014; 115(1):97-107. PMC: 4094348. DOI: 10.1161/CIRCRESAHA.115.302929. View

2.
Borlaug B, Olson T, Lam C, Flood K, Lerman A, Johnson B . Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56(11):845-54. PMC: 2950645. DOI: 10.1016/j.jacc.2010.03.077. View

3.
Chinkers M, Garbers D, Chang M, Lowe D, Chin H, Goeddel D . A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 1989; 338(6210):78-83. DOI: 10.1038/338078a0. View

4.
Borlaug B, Anstrom K, Lewis G, Shah S, Levine J, Koepp G . Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. JAMA. 2018; 320(17):1764-1773. PMC: 6248105. DOI: 10.1001/jama.2018.14852. View

5.
Reddy Y, Andersen M, Obokata M, Koepp K, Kane G, Melenovsky V . Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 70(2):136-148. PMC: 5520668. DOI: 10.1016/j.jacc.2017.05.029. View